Avantis International Large Cap Value ETF AVIV 深 沪
等待开盘 12-20 09:30:00 美东时间
70.87
+0.550
+0.78%
华盛通- 最 高70.94
- 今 开70.83
- 成交量 2.17万股
- 最 低 70.80
- 昨 收 70.32
- 总市值 8.57亿
- 52周最高 70.962
- 市盈率 静 --
- 换手率 0.18%
- 52周最低 47.7029
- 委 比 50.00%
- 总股本 1209.00万
- 历史最高 70.962
- 量 比 1.07
- 振 幅 0.20%
- 历史最低 31.2619
- 每 手 1
- 风险率 6.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ZOOZ Launches New Dashboard And Cuts Costs
TEL AVIV, Israel, Dec. 16, 2025 /PRNewswire/ -- ZOOZ Strategy is launching an interactive new dashboard, provided by a third party and designed to provide an up to date and accessible snapsh...
12-16 21:46
SuperCom Expands into 15th New State with New Electronic Monitoring Contract in North Carolina
SuperCom continues its track record of displacing incumbent vendors and secures 16th new service provider partnership since mid-2024 TEL AVIV, Israel, Dec. 16, 2025 /PRNewswire/ -- SuperCom...
12-16 20:43
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a therapeutic challenge, wit...
12-15 20:00
SuperCom Wins New Electronic Monitoring Contract in Texas, Expands U.S. Footprint into 14th State
Juvenile probation agency selects SuperCom to replace incumbent vendor and modernize offender monitoring programs TEL AVIV, Israel, Dec. 4, 2025 /PRNewswire/ -- SuperCom (NASDAQ: SPCB), a gl...
12-04 22:00
Galmed Issues CEO Letter to Shareholders
TEL AVIV, Israel, Dec. 1, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometa...
12-01 21:30
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 1, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced th...
12-01 20:00
Teva Pharmaceuticals International GmbH Wins EU Approval For Denosumab Biosimilars PONLIMSI And DEGEVMA
Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva's biosimilars PONLIMSI and DEGEVMA expanding access to
11-25 21:11
RADCOM Secures Contract for Smart Network Visibility Solution through Rakuten Symphony
TEL AVIV, Israel, Nov. 18, 2025 /PRNewswire/ -- RADCOM Ltd. (Nasdaq: RDCM) announced today that it has secured a contract for its Smart Network Visibility Solution through Rakuten Symphony f...
11-18 20:00
SuperCom Announces New Electronic Monitoring Service Provider Contract In Missouri
New win marks SuperCom's 13th U.S. state entry and 15th service provider partnership since mid-2024 as SuperCom broadens U.S. footprintTEL AVIV, Israel, Nov. 17, 2025 /PRNewswire/ -- SuperCom (NASDAQ: SPCB), a
11-17 22:14
Chemomab To Present Abstracts Highlighting New Clinical Data From Nebokitug Phase 2 SPRING Trial In Primary Sclerosing Cholangitis, At AASLD 2025
— Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks——New Clinical Data Provides Insights on
11-06 21:09
